Scientific News Boston Scientific Resumes Farapulse Pulsed Field Ablation Study In First Line Afib
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Boston Scientific Resumes Farapulse Pulsed Field Ablation Study In First Line Afib is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Boston Scientific’s global pulsed field ablation trial targets persistent atrial fibrillation growth
Boston Scientific ($BSX) announced an update on their ongoing clinical study. Study OverviewThis global Boston Scientific trial, officially titled ... Read More
Year in Review: Pulsed-Field Ablation Again Tops Heart Rhythm News
Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs. Read More
Newer pulsed field ablation ‘already as effective’ as radiofrequency ablation
Please provide your email address to receive an email when new articles are posted on . AF recurrence after pulsed field ablation was comparable vs. after radiofrequency ablation. There were fewer ... Read More
Boston Scientific: Gangbusters Growth, And A Valuation To Match
Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX stock here. Read More
Boston Scientific claims European approval for Farapoint focal pulsed field ablation catheter
Boston Scientific has obtained an approval in Europe for the latest addition to its pulsed field ablation portfolio, with the Farapoint focal catheter. The CE mark brings a new indication to the ... Read More
Abbott's Volt pulsed field ablation system scores FDA approval
After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U. Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus